HLA-B*5701 Typing
Use
Abacavir therapy for HIV treatment is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong association with the HLA-B*5701 allele. HLA-B*5701 typing can be used for genetic risk stratification prior to initiation of Abacavir therapy.
Special Instructions
Not provided.
Limitations
A negative result does not rule out the risk for abacavir hypersensitivity (ABC HSR) and clinical vigilance should be maintained regardless of the result.
Methodology
PCR-based (PCR)
Biomarkers
HLA-B*5701 Allele
Other
Result Turnaround Time
8 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL (preferred)
Minimum Volume
3 mL
Container
EDTA (lavender-top) tube
Collection Instructions
Separate EDTA (lavender-top) tube; do not open tube; submit separate from other tests.
Causes for Rejection
Received frozen • Clotted
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
Other tests from different labs that may be relevant